文章：

CAR-T细胞在急性淋巴细胞白血病（ALL）治疗中的应用综述

Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study 

原文发布日期：2022-01-05 

英文摘要：

Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and consolidation chemotherapy alone or in combination with different therapeutic approaches remain the main treatment. Although complete or partial remission of the disease can be achieved, the risk of relapse or refractory leukemia is still high. More effective and safe therapy options are yet unmet needs. In recent years’ new therapeutic approaches have been widely used. Hematopoietic Stem Cell Transplantation (HSCT) presents significant limitations and the outcome of the consolidation treatment is patient dependent. Side effects such as Graft versus Host Disease (GvHD) in allogeneic hematopoietic stem cell transplantation are extremely common, therefore, using alternative methods to address these challenges for treatment seems crucial. In the last decade, T cells genetically engineered with Chimeric Antigen Receptor (CAR) treatment for the ALL are largely studied and represent the new era of strategy. According to the Phase I/II clinical trials, this technology results seem very promising and can be used in the next future as an effective and safe treatment for ALL treatment. In this review different generations, challenges, and clinical studies related to chimeric antigen receptor (CAR) T-cells for ALL treatment are discussed. 

摘要翻译： 

急性淋巴细胞白血病（ALL）是一种特异性针对淋巴细胞的恶性肿瘤。诱导和巩固化疗，无论是单独使用还是与其他治疗方法联合应用，目前仍是主要治疗手段。尽管可以实现疾病的完全或部分缓解，但复发或难治性白血病的风险仍然很高。更有效且安全的治疗方案仍是未满足的医疗需求。近年来，新型治疗方法得到广泛应用。造血干细胞移植（HSCT）存在显著局限性，且巩固治疗的效果因患者个体差异而不同。异基因造血干细胞移植中移植物抗宿主病（GvHD）等副作用极为常见，因此采用替代方法应对这些治疗挑战显得至关重要。过去十年中，采用嵌合抗原受体（CAR）基因工程改造的T细胞治疗ALL得到广泛研究，代表了治疗策略的新纪元。根据I/II期临床试验结果，该技术展现出巨大应用前景，有望成为未来ALL治疗的有效且安全的手段。本综述讨论了用于ALL治疗的不同代次CAR-T细胞、面临的挑战及相关临床研究。

原文链接：

Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study